Keyphrases
Asia
100%
Prospective Observational Study
100%
Stroke Prevention in Atrial Fibrillation
100%
Rivaroxaban
100%
Once-daily
50%
Non-valvular Atrial Fibrillation
50%
Systemic Embolism
50%
All-cause Mortality
33%
Asia-Pacific
33%
ROCKET-AF
33%
Adverse Events
16%
East Asia
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Low Dose Rate
16%
Hypertension
16%
Confidence Interval
16%
Myocardial Infarction
16%
Treatment Duration
16%
Central Nervous System
16%
Heart Failure
16%
Non-central
16%
Warfarin
16%
Comorbidity
16%
Major Bleeding
16%
Bleeding
16%
Transient Ischemic Attack
16%
Serious Adverse Events
16%
Major Bleeding Events
16%
Anticoagulant Therapy
16%
Routine Care
16%
CHADS2
16%
CHA2DS2-VASc
16%
Treatment Emergent
16%
Prior Stroke
16%
XANTUS
16%
Real-world Observational Study
16%
Pharmacology, Toxicology and Pharmaceutical Science
Observational Study
100%
Atrial Fibrillation
100%
Cerebrovascular Accident
100%
Rivaroxaban
100%
Adverse Event
33%
Bleeding
33%
All Cause Mortality
33%
Heart Infarction
16%
Diabetes Mellitus
16%
Warfarin
16%
Transient Ischemic Attack
16%
Congestive Heart Failure
16%
Anticoagulation Therapy
16%
Comorbidity
16%